Basiliximab is named as an intervention in 3 current clinical trials in our China, France and Italy registers. 1 is recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Anhui Provincial Hospital (1). The most-studied condition is Acute Graft Versus Host Disease.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies
NCT05385432 · ClinicalTrials.gov ↗ · Renal Transplant Rejection, Induction Therapy
|
Phase 3 | Recruiting | University Hospital, Tours | France |
|
Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases
NCT06480630 · ClinicalTrials.gov ↗ · Acute Graft Versus Host Disease, Malignant Hematologic Neoplasm
|
Phase 2 | Not yet open | Anhui Provincial Hospital | China |
|
1 vs 7 RATG Infusions in Renal Transplantation
NCT06374095 · ClinicalTrials.gov ↗ · Kidney Replacement
|
Observational | Active, closed | Mario Negri Institute for Pharmacological Research | Italy |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
2 single-substance products containing Basiliximab on the HPRA medicines list.
No entry for Basiliximab in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Anhui Provincial Hospital | 1 |
| University Hospital, Tours | 1 |
| Mario Negri Institute for Pharmacological Research | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 0 |
| Clinical trials in France | 1 | 1 |
| Clinical trials in Italy | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China, France and Italy registers name Basiliximab as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 3 trials is recruiting: 1 with sites in France. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Anhui Provincial Hospital (1), University Hospital, Tours (1) and Mario Negri Institute for Pharmacological Research (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 2 single-substance products containing Basiliximab, for example Simulect 10 mg powder and solvent for solution for injection or infusion (Novartis Europharm Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Basiliximab has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Basiliximab works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Basiliximab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Basiliximab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.